Catal­ent in­tro­duces new AAV gene ther­a­py tech in aim to speed up man­u­fac­tur­ing process

As Catal­ent ven­tures fur­ther in­to the world of cell and gene ther­a­py man­u­fac­tur­ing, the New Jer­sey-based CD­MO has re­vealed its new ade­no-as­so­ci­at­ed vi­ral vec­tor plat­form.

The Up­Tem­po Vir­tu­oso plat­form can stream­line the AAV man­u­fac­tur­ing process to cut back on the time it takes to go from clin­ic to in-hu­man clin­i­cal tri­als. It in­cludes pro­to­cols for cell cul­ture, trans­fec­tion, and down­stream pu­rifi­ca­tion, and can sim­pli­fy the crit­i­cal sup­ply chain. It’s de­signed to pro­duce prod­ucts for the clin­ic in just nine months, Catal­ent says, and cus­tomers will have ac­cess to Catal­ent’s plas­mid DNA of­fer­ings, too.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER